Enter multiple symbols separated by commas



  • Holograms in healthcare Monday, 15 Jun 2015 | 1:19 PM ET
    Holograms in healthcare

    CNBC's Meg Tirrell gives an inside look at futuristic holograms and the high tech advancements being made possible for the biotech space.

  • Biotech goes high tech inside a virtual body Monday, 15 Jun 2015 | 11:58 AM ET
    Biotech goes high tech inside a virtual body

    What does the future of healthcare look like? CNBC's Meg Tirrell reports live in Philadelphia at the Klick Ideas exchange with a closer look.

  • June 15- Drugstore operator CVS Health Corp said it will acquire Target Corp's U.S. pharmacy and clinics businesses in a $1.9 billion deal that will help it bargain with drug makers for lower prices. "The addition of the Target pharmacy adds significant purchasing clout for pharmaceuticals," FBR Capital markets analyst Steven Halper wrote in a note.

  • -Clinton@- Democratic presidential candidate Hillary Clinton said on Sunday that drug companies that would benefit from a Pacific trade deal should sell their products to the U.S. government at a discount. "I think our drug companies, if they're going to get what they want, they should give more to America. They should be required to negotiate drug prices in America...


  • Bets ahead of experimental Alzheimer's drug Friday, 12 Jun 2015 | 3:18 PM ET
    Bets ahead of experimental Alzheimer's drug

    CNBC's Meg Tirrell reports on the latest Alzheimer's data.

  • New Alzheimer's drugs timeline Friday, 12 Jun 2015 | 1:05 PM ET
    New Alzheimer's drugs timeline

    How Alzheimer's drug Solanezumab works to help treat the underlying cause of the disease, with CNBC's Meg Tirrell.

  • SHANGHAI, June 12- The World Health Organization has approved a Chinese influenza vaccine as being safe and effective, only the second Chinese vaccine to receive such status reflecting the growing clout of the country's drug makers. The WHO said in a statement on Friday that it had "prequalified" a vaccine made by Hualan Biological Bacterin Corp, a subsidiary of...

  • Lilly shares sizzle as investors await Alzheimer's data Thursday, 11 Jun 2015 | 9:18 PM ET

    June 11- Shares of Eli Lilly and Co have jumped 10 percent this week, confounding many industry experts, amid speculation investors were placing bets ahead of expected long-term data on an Alzheimer's disease treatment once considered a dud. Limited data from an abstract of the trial, called Expedition Ext, are expected to be released by the Alzheimer's...

  • Bill aimed at 'patent trolls' advances in U.S. House Thursday, 11 Jun 2015 | 6:22 PM ET

    NEW YORK, June 11- A U.S. congressional panel on Thursday approved a bill aimed at deterring frivolous patent lawsuits, but which some critics say undermines the ability to protect new innovations. The U.S. House of Representatives Judiciary Committee, in a 24-8 bipartisan vote, sent the measure to the full House, a move reflecting lawmakers' desire to neutralize...

  • Axovant largest biotech IPO ever Thursday, 11 Jun 2015 | 3:15 PM ET
    Axovant largest biotech ever

    CNBC's Bob Pisani has the story on biotech stock Avovant, which has an Alzheimer's disease drug entering phase 3 trials.

  • More than a third of India's 2.1 million HIV/AIDS patients depend on getting their daily antiretrovirals for free from state-run distribution centres, but many of them have been facing shortages or stock outs for months. The notice put out by the Central Board of Excise and Customs this week intends to make it cheaper to import raw materials that are used to...

  • Watershed moment for 'female Viagra' Thursday, 11 Jun 2015 | 5:20 AM ET
    Watershed moment for 'female Viagra'

    Cindy Whitehead, co-founder and CEO of Sprout Pharmaceuticals, discusses its drug "flibanserin," also known as the "female Viagra."

  • The pharma sector is exciting, says Wells Fargo Wednesday, 10 Jun 2015 | 7:24 PM ET
    The pharma sector is exciting, says Wells Fargo

    Margaret Patel, senior portfolio manager & managing director at Wells Fargo Advantage Funds, explains why she likes U.S. pharmaceutical stocks.

  • China graft probes a tough tonic as pharma margins bounce Wednesday, 10 Jun 2015 | 5:00 PM ET

    Faster growth in China is good news for local and global firms chasing a medicine bill estimated by IMS Health to hit $185 billion by 2018, but who have taken a hit from a series of bribery probes that led to a $500 million fine against British drugmaker GlaxoSmithKline PLC last year. "Sales departments did slow down activities in China and have taken their time to...

  • Esperion sinks Wednesday, 10 Jun 2015 | 2:58 PM ET
    Esperion sinks

    CNBC's Meg Tirrell reports the latest action happening in the cholesterol drug pipeline.

  • LONDON, June 10- AstraZeneca's chief medical officer and head of global late-stage drug development Briggs Morrison is to leave the company, creating a gap at the top of the group's research operations. A spokeswoman said on Wednesday Morrison was departing to become chief executive of an unlisted venture capital-backed drugmaker in the United States,...

  • FDA panel backs first-in-class cholesterol drug Wednesday, 10 Jun 2015 | 8:44 AM ET
    Leonard Schliefer, CEO of Regeneron.

    Federal health advisers recommended approval for a highly anticipated cholesterol drug from Sanofi and Regeneron Pharmaceuticals, but with a caveat.

  • Two drugs target 'bad' cholesterol: CEO Wednesday, 10 Jun 2015 | 7:21 AM ET
    Two drugs target 'bad' cholesterol: CEO

    Regeneron CEO Leonard Schleifer talks about an FDA panel's approval of Sanofi-Regeneron's new cholesterol-lowering drugs.

  • Cholesterol drug wars Tuesday, 9 Jun 2015 | 5:25 PM ET
    Cholesterol drug wars

    CNBC's Meg Tirrell reports on a key ruling by an FDA panel on new cholesterol drug Praluent. At least one "Fast Money" trader would rather own Amgen than Regeneron.